SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin zooms on plan to launch Combivir in US

14 May 2012 Evaluate

Giving a boost to its declining bottomline, the drug maker, Lupin is all set to launch the generic version of anti-HIV drug, Combivir in the USA. The said drug is the combination of lamividine and zidovudine tablets and is prescribed in combination with other antiretroviral agents for the treatment of HIV-1 infection. The company is waiting for final approval from US Food and Drug Administration (FDA).

Lupin is currently trading at Rs. 537.90, up by 21.40 points or 4.14% from its previous closing of Rs. 516.50 on the BSE.

The scrip opened at Rs. 518.00 and has touched a high and low of Rs. 540.00 and Rs. 515.80 respectively. So far 49963 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 574.05 on 17-Apr-2012 and a 52 week low of Rs. 404.55 on 13-May-2011.

Last one week high and low of the scrip stood at Rs. 559.50 and Rs. 507.70 respectively. The current market cap of the company is Rs. 24032.02 crore.

The promoters holding in the company stood at 46.93% while Institutions and Non-Institutions held 44.05% and 9.02% respectively.

Lupin Share Price

2311.75 -16.85 (-0.72%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×